Analytical Data
-
Gene name
MAGEA6
- Application
-
Alternative Names
Cancer/testis antigen 1.6 (CT1.6) (MAGE-6 antigen) (MAGE3B antigen) (MAGE6)
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P43360
-
Expression Region
1-314aa
-
Molecular Weight
42.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MAGEA6, a member of the cancer/testis antigen family, has garnered significant attention in cancer research due to its restricted expression pattern, being primarily found in germ cells and various tumors, particularly melanoma and breast cancer. The unique expression of MAGEA6 in cancer cells, while absent in most normal tissues, makes it a promising target for immunotherapy and vaccine development. Recent studies have sought to understand the molecular mechanisms underlying MAGEA6 expression and its role in tumorigenesis, which may provide insights into cancer progression and potential therapeutic strategies. Recombinant MAGEA6 protein has been utilized in functional assays to assess its immunogenicity and potential as a target for T-cell responses. Additionally, MAGEA6's role as an inhibitor of apoptosis highlights its significance in cancer cell survival, making it a critical focus for future studies aimed at developing targeted therapies. Understanding the structure and function of recombinant MAGEA6 could pave the way for novel strategies in cancer treatment, capitalizing on its unique characteristics as a tumor-associated antigen.
